London, United Kingdom, August 17, 2019 --(PR.com)-- SMi Group Reports: NICOX recently announced that they have successfully tested a new treatment for the reduction of intraocular pressure in glaucoma. The NCX 470 Clinical Study went head-to-head on a daily dose of the treatment versus Latanoprost, which is perceived as the number one treatment for glaucoma and ocular hypertension.

Gavin Spencer who is Executive Vice President & Chief Business Officer, will be presenting at the third annual Ophthalmic Drugs Conference, where he will discuss the development of NCX 470. He will also focus on the role of nitric acid in control intraocular pressure and future generation compounds from the NICOX platform.

On Day Two of the conference, under the same discussion point on New Developments in Ophthalmic Clinical Trials and Drug Development, Parisa Zamiri, Global Head of Clinical Development in Ophthalmology at Novartis Pharmaceutical will discuss the transformation of future eye care and Virginia Calder, Reader in Ocular Immunology from UCL Institute of Ophthalmology highlights the use of experimental models to identify potential anti-inflammatory drugs in allergic conjunctivitis and uveitis.

Other high-profile speakers presenting include:
Aniz Girach, Chief Medical Officer, ProQR Therapeutics
Daniel Chung, Global Medical Strategy Lead-Ophthalmology, Spark Therapeutics
Michael Ehrlich, Senior Clinical Program Lead - Retinopathies, Boehringer Ingelheim
Peter Morgan-Warren, Medical Assessor, MHRA

Further details about the event can be found on the website www.ophthalmicdrugs.com/pr4

Sponsored by:
EXPERIMENTICA | ProMed Pharma

Contacts:
Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168

Delegate enquiries: contact Alex Vidic on: +44 (0) 20 3866 0221

Media enquiries contact Neill Howard +44 (0) 207 827 6164